The pathogenesis of severe COVID-19 reflects an inefficient immune reaction to SARS-CoV-2.
Here we analyze, at the single cell level, plasmablasts egressed into the blood to study …

Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and
is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in …

The third edition of Flow Cytometry Guidelines provides the key aspects to consider when
performing flow cytometry experiments and includes comprehensive sections describing …

Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against
hematological malignancies. The current dominant manufacturing approach for CAR T cells …

Background and purpose A fraction of patients with antibody‐mediated autoimmune
diseases remain unresponsive to first‐/second‐line and sometimes even to escalation …

The anti-CD38 antibody daratumumab is approved for treatment of refractory multiple
myeloma and acts by depletion of plasma cells and modification of various T-cell functions. Its …

Given its uniformly high expression on plasma cells, CD38 has been considered as a therapeutic
target in patients with systemic lupus erythematosus (SLE). Herein, we investigate the …

Diverse autoantibodies were suggested to contribute to severe outcomes of COVID‐19, but
their functional implications are largely unclear. ACE2, the SARS‐CoV‐2 receptor and a key …

Objective: To investigate whether low-density granulocytes (LDGs) are an immunophenotypic
feature of patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (…

Objective Treatment-refractory antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is a life-threatening condition without evidence-based treatment options. One …